PL1868614T3 - Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem - Google Patents

Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Info

Publication number
PL1868614T3
PL1868614T3 PL06748657T PL06748657T PL1868614T3 PL 1868614 T3 PL1868614 T3 PL 1868614T3 PL 06748657 T PL06748657 T PL 06748657T PL 06748657 T PL06748657 T PL 06748657T PL 1868614 T3 PL1868614 T3 PL 1868614T3
Authority
PL
Poland
Prior art keywords
progesterone
treatment
brain injury
dosage regimen
traumatic brain
Prior art date
Application number
PL06748657T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellermann
Donald G Stein
David W Wright
Douglas W Lowery-North
Sarah Melissa Cutler
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of PL1868614T3 publication Critical patent/PL1868614T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
PL06748657T 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem PL1868614T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
PCT/US2006/010797 WO2006102596A2 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
PL1868614T3 true PL1868614T3 (pl) 2013-01-31

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Country Status (16)

Country Link
US (4) US20090325920A1 (pl)
EP (5) EP2431042B1 (pl)
JP (5) JP5394059B2 (pl)
AT (2) ATE499104T1 (pl)
AU (2) AU2006226811B2 (pl)
CA (2) CA2601715C (pl)
CY (2) CY1111478T1 (pl)
DE (1) DE602006020353D1 (pl)
DK (2) DK1868614T3 (pl)
ES (2) ES2392454T3 (pl)
HK (3) HK1112579A1 (pl)
HR (2) HRP20110198T1 (pl)
PL (2) PL2030622T3 (pl)
PT (2) PT1868614E (pl)
RS (1) RS52471B (pl)
WO (2) WO2006102596A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2431042B1 (en) * 2005-03-24 2013-06-26 Emory University Methods for the treatment of central nervous system injury via a tapered administration protocol
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
CA2955684A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US10231976B2 (en) 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
KR20140043078A (ko) * 2011-04-27 2014-04-08 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN112472814A (zh) * 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经***障碍的方法
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
MX2014010445A (es) 2012-02-29 2014-10-13 Braun Melsungen Ag Emulsion que contiene hormona que comprende fosfolipidos de kril.
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
PT2887944T (pt) * 2012-08-21 2022-01-10 Sage Therapeutics Inc Alopregnanolona para tratamento do estado de mal epiléptico refratário
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
SG11201505934XA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105408336B (zh) 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
TWI798173B (zh) 2016-03-08 2023-04-11 美商賽吉醫療公司 神經活性類固醇，其組合物及用途
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US20230190709A1 (en) * 2021-12-02 2023-06-22 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
WO1994016709A2 (en) * 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
UA57706C2 (uk) * 1995-06-06 2003-07-15 Косенсіз, Інк Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти)
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0954260A1 (en) 1996-05-22 1999-11-10 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
KR20010012157A (ko) 1997-05-02 2001-02-15 이곤 이 버그 프레그난-3-올-20-온
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2431042B1 (en) * 2005-03-24 2013-06-26 Emory University Methods for the treatment of central nervous system injury via a tapered administration protocol

Also Published As

Publication number Publication date
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
EP2431042B1 (en) 2013-06-26
JP2014055183A (ja) 2014-03-27
EP2030622B1 (en) 2011-02-23
JP5295755B2 (ja) 2013-09-18
CA2602950C (en) 2012-10-30
DK1868614T3 (da) 2012-11-12
HRP20120688T1 (hr) 2012-09-30
WO2006102644A9 (en) 2006-11-23
WO2006102644A2 (en) 2006-09-28
ATE520404T1 (de) 2011-09-15
WO2006102596A2 (en) 2006-09-28
JP2008534512A (ja) 2008-08-28
AU2006226774A1 (en) 2006-09-28
EP1871382B1 (en) 2011-08-17
WO2006102644A3 (en) 2007-03-01
US20090221544A1 (en) 2009-09-03
PT2030622E (pt) 2011-06-02
CY1111478T1 (el) 2015-08-05
CA2602950A1 (en) 2006-09-28
EP2030622A1 (en) 2009-03-04
RS52471B (en) 2013-02-28
US20120245133A1 (en) 2012-09-27
DE602006020353D1 (de) 2011-04-07
PT1868614E (pt) 2012-11-23
JP2013234191A (ja) 2013-11-21
US20090325920A1 (en) 2009-12-31
CA2601715A1 (en) 2006-09-28
EP2431042A1 (en) 2012-03-21
AU2006226774B2 (en) 2010-12-02
HK1128242A1 (en) 2009-10-23
HK1112579A1 (en) 2008-09-12
EP1868614A2 (en) 2007-12-26
HK1112581A1 (en) 2008-09-12
AU2006226811B2 (en) 2010-11-25
US8614203B2 (en) 2013-12-24
EP1868614B1 (en) 2012-08-08
JP5496407B2 (ja) 2014-05-21
EP2494976A1 (en) 2012-09-05
JP5394059B2 (ja) 2014-01-22
PL2030622T3 (pl) 2011-07-29
JP2011225629A (ja) 2011-11-10
CY1113253T1 (el) 2016-04-13
JP2008534515A (ja) 2008-08-28
US20120289491A1 (en) 2012-11-15
HRP20110198T1 (hr) 2011-04-30
EP1871382A2 (en) 2008-01-02
ES2392454T3 (es) 2012-12-10
DK2030622T3 (da) 2011-05-02
ATE499104T1 (de) 2011-03-15
WO2006102596A3 (en) 2007-01-18
AU2006226811A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
HK1112579A1 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
HK1213939A1 (zh) 再生用於在神經系統中治療疾病和損傷的功能性神經元
WO2016025635A3 (en) Combination therapy for treating cancer
WO2005070052A3 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
WO2008033792A3 (en) Repetitive transcranial magnetic stimulation for movement disorders
TN2019000332A1 (en) Methods of treating pediatric cancers
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
PL1913947T3 (pl) Terapia skojarzona do leczenia raka
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
HK1095285A1 (en) Benzamidine derivatives for treatment and prevention of mucositis
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
WO2018060528A3 (en) Therapeutic protein
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2017197249A3 (en) METHODS OF TREATING HYPER-BILIRUBINEMIA USING STANNSOPORFIN AND PHOTOTHERAPY
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students
Haas Treatment of choice in superficial basal cell carcinoma.
GB202218314D0 (en) Vitamin a for use in the treatment of traumatic brain injury
Peter Celecoxib/thalidomide/temozolomide